FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
Toxicity hits BioNTech’s MediLink tie-up
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
ASCO 2024 preview – waiting for Blueprint and Caribou
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
ESMO Breast Cancer 2024 – Olema digs deep to declare victory
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
